While CD38‐targeting antibodies were initially developed to kill malignant plasma cells, these monoclonal antibodies may also abrogate the production of autoantibodies in autoimmune disorders and thereby reduce autoantibody‐dependent effector mechanisms. The gene discussed is CD38; the disease is autoimmune disease.